News GSK wins the vote contest in FDA’s RSV vaccine panels Advisory committee votes unanimously that RSVPreF3 shot is effective, and 10-2 on safety.
News Pfizer’s RSV shot clears FDA adcomm; now it’s GSK’s turn There was debate about cases of Guillain Barré and the population of the phase 3 RENOIR trial.
News Forget Merck, now Pfizer is said to be after Seagen Rumour of negotiations comes as Pfizer is facing a steep patent cliff in the next few years.
Oncology Pfizer’s bispecific elranatamab and future oncological care Pfizer announced that the FDA granted Priority Review for its BLA for bispecific elranatamab.
News Protocol violations gut Pfizer’s Lyme disease shot study 50% of US patients in the VALOR study of VLA15 will be discontinued from the trial.
News Lynparza under siege in first-line prostate cancer New data from Pfizer and J&J encroach on AZ and Merck's territory with the PARP inhibitor.
News Sanofi's Dupixent scores double COPD win in US, China Originally anticipated in June, the FDA action stands to make Sanofi and Regeneron's biologic blockbuster even bigger.
Sales & Marketing Sponsored Shifting the paradigm in pharma marketing with content trans... Content transformation is changing pharmaceutical marketing. Join us to learn new strategies and approaches for this new world of patient centricity.